期刊文献+

非生理性起搏与生理性起搏患者血浆脑钠素的变化及其意义

Changes of Plasma Brain Natriuretic Peptide and It's Impact in Patients with Physiological and Non - physiological Pacing
下载PDF
导出
摘要 目的:为弄清不同起搏模式对血浆脑钠素(BNP)水平影响的差异及意义。方法:选择门诊进行随访的已安置起搏器的病人57例,按起搏方式分为生理性起搏组(n=23例)和非生理性起搏组(n=34例),另选同期进行体检健康者20例作为对照组,测定其血浆BNP水平、超声心动图指标。结果:非生理性起搏组BNP浓度高于生理性起搏组和组照组[(89.34±25.11) pg/ml vs(56.33±47.62)pg/ml,(30.35±8.51)pg/ml,P均<0.01];生理性起搏组BNP浓度高于对组照组(P<0.01);非生理性起搏组射血分数明显低于生理性起搏组及对照组[(0.44±0.12)vs(0.56±0.07),(0.65±0.10),P均<0.01),生理性起搏组EF又明显低于对照组(P<0.01)。结论:起搏会引起BNP升高,尤以非生理起搏最明显,此与心功能水平有关。 Objective:To explore the changes of plasma brain natriuretic peptide(BNP) and it's impact in patients vvith physiological and non - physiological pacing.Methods:The subjects consisted of 57 outpatients with implanted pennanent pacemakers for at least 6 months.They were divided into the physiological pacing group(DDD,n = 23)and non - physiological pacing group(VVI,n = 34). 20 cases healthy persons were elected as the control group. Plasma BNP were measured and echocardigrams were also taken. Results: Plasma BNP level was significantly higher in the non - physiological pacing group than in the physiological pacing group and in the control group [ (89. 34±25. 11) pg/mlvs (56. 33±47.62) pg/ml, (30.35±8.51) pg/ml, allP < 0.01] .It was also significantly higher in the physiological pacing group than in the control group (P < 0.01). Left ventricular ejection fraction (LVEF) was significantly lower in the non - physiological pacing group than in the physiological pacing group and in the control groupt (0.44±0.12) vs (0.56±0.07), (0.65±0.10), all P<0.01]. It was also significantly lower in the physiological pacing group than in the control group (P < 0.01) .Conclusion: Pacing could elicit high plasma BNP,especially in the patients with non - physiological pacing and it could be correlated vvith bad LVEF.
出处 《中国医药导刊》 2005年第3期159-160,共2页 Chinese Journal of Medicinal Guide
关键词 非生理性起搏 生理性起搏 血浆脑钠素 心功能 Cardiac pacing Brain natriuretic peptide Cardiac function
  • 相关文献

参考文献8

  • 1Wada A, Tsutamoto T, Kinoshita M, et al. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclasecouoled receptors. Circulation. 1994; 89: 2232-2240.
  • 2Lang GG, Choy AM J, Struthers AD. Atrial and brain natriuretic peptides :A dual natriuretic pepfide system potentially involved in circulatory homeostasis. Clin Sci. 1992; 83 : 519-527.
  • 3Blanc JJ, Mansourati J, Ritter P.Atrial natriurefic factor release during exercise in patients successively pacing in DDD and rate-matched ventricular Pacing. PACE, 1992; 15:397-402.
  • 4Tsutamoto T, Wade A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuetic peptide system in chronic heart failure:Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation, 1997:96:509- 516.
  • 5Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature, 1998; 322: 78-80.
  • 6Mcnainy M, Gardetto N, Clopton P, et al .Statility of B - type natriuretic peptide levels during exercise in patients with congestive heart failure:Implication for outpatient monitoring with B - type natriuetic peptide. Am Heart J,2002; 143(3) :406.
  • 7杨传高,李红霞,程绪杰,杨俊华,宋建平.脑利钠肽浓度评估慢性充血性心力衰竭[J].临床内科杂志,2004,21(6):388-390. 被引量:12
  • 8吴荣,李卫华,滕志涛,马欲晓,张丽娟,谢强.心脏起搏对血浆脑利钠肽影响的临床研究[J].中国心脏起搏与心电生理杂志,2004,18(4):275-276. 被引量:10

二级参考文献11

  • 1Ogawa Y,Itoh H,Nakao K. Molecular biology and biochemistry of natriuretic peptide family[J]. Clin Exp Pharmacol Physiol,1995,22:49
  • 2Cowie MR,Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing[J]. Eur Heart J, 2003, 24: 1 710
  • 3Hosada K,Nakao K,Mukoyama M,et al. Expression of brain natriuretic peptide gene.Production in the venotricle[J]. Hypertension,1991,17:1 152
  • 4Horie H,Tsutamoto T,Minai K,et al.Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome[J].Jpn Cire J ,2000,64:965
  • 5Dao Q,Krishnaswamy P,Kazanegra R, et al. Utilty of B-type natriuretic peptide in the diagnosis of congestive heart failure from lung disease in patients presenting with dyspnea[J]. J Am Coll Cardial,200l,37:379
  • 6Wiese S,Breyer T,Dragu A,et al.Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium:influence of angiotensin Ⅱ and diastolic fiber length.Circulation ,2000,102 (25):3074-3079.
  • 7Dao Q ,Krishnaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting.J Am Coll Cardiol,2001,37(2):379-385.
  • 8Davis M,Espiner E,Richards G,et al.Plasma brain natriuretic peptide in assessment of acute dyspnoea.Lancet,1994,343(8895):440-444.
  • 9Maisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med,2002,347(3):161-167.
  • 10Maisel AS,Hlavin P,McCord J,et al.B-Type natriuretic peptide in the emergency diagnosis of diastolic dysfunction heart failure.J Am Coll Cardiol,2002,39( Suppl A):1061-1156.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部